Navigation Links
iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
Date:4/1/2009

Study Includes iCardiac's Highly Automated QT(sm) Solution

Rochester, New York (PRWEB) April 1, 2009 -- iCardiac Technologies announced today that its advanced cardiac safety biomarkers were used successfully in a clinical study to model the effect of a serious disease on the heart's repolarization process.

The repolarization biomarkers, captured on a continuous electrocardiogram, played a key role in helping a leading pharmaceutical company to model the effects of disease on cardiac repolarization. The information provided by iCardiac's advanced morphological biomarkers enables drug developers to separate reliably the cardiac effects triggered by experimental drugs.

"This is an important step for cardiac safety testing," said iCardiac's Co-Founder and Executive Vice President Sasha Latypova. "Up until now there has not been a means for pharmaceutical companies to separate conclusively QT prolongation that originates with the disease state from that which stems from the drug being tested."

iCardiac's advanced ECG-based biomarkers enable a comprehensive evaluation of cardiac repolarization morphology and dynamics. The repolarization process - represented by what is called the QT interval, as measured on an ECG - is the brief period of time between two heart beats and is known to be a vulnerable time for arrhythmia induction. In rare instances, drug-induced arrhythmias can lead to sudden cardiac death.

iCardiac's COMPAS software platform performs digital quantification of repolarization abnormalities and enables measurement of subtle differences in ECG signals that may indicate arrhythmia predisposition. iCardiac's validation studies conducted at the University of Rochester have demonstrated that quantification of such morphological changes complement and improve upon information gathered from QT interval studies.

The study also included iCardiac's validated Highly Automated QT analysis. The highly automated solution combines advanced ECG signal processing algorithms developed over the past decade with a robust quality assurance process conducted by cardiologists. It has been validated in over 10 clinical QT studies and has been accepted by the FDA as equivalent to the manual evaluation of ECGs in Through QT studies.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/cardiac/safety/prweb2253204.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
3. Saddam Lawyer Applies for Pardon for Dr Crippen
4. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
5. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
6. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
7. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
8. Advanced Life Sciences Receives Notice of Planned Cethromycin Review by FDA Advisory Committee
9. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
10. Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results
11. Nasdaq Panel Grants Advanced Life Sciences Request for Continued Listing on Nasdaq Stock Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher of ... Desktop modules to its flagship X-Win32 PC X server. The new modules enable ... user’s PC over encrypted SSH. , Traditionally, users of PC X servers deploy the ...
(Date:4/29/2016)... New York , April 29, 2016 /PRNewswire/ ... report published by Transparency Market Research "Separation Systems ... Size, Share, Growth, Trends, and Forecast 2015 - ... was valued at US$ 10,665.5 Mn in 2014 ... of 6.8% from 2015 to 2023 to reach ...
(Date:4/28/2016)... The report "Cryocooler Market by ... (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, and ... 2022", published by MarketsandMarkets, the global market is expected ... a CAGR of 7.29% between 2016 and 2022. ... Figures spread through 159 Pages and in-depth TOC on ...
(Date:4/28/2016)... Windsor, Connecticut (PRWEB) , ... April 28, 2016 ... ... Morris Group, Inc., will hold an open house for regional manufacturers at its ... and displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):